Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway.

• DOI: 10.1200/jco.2018.36.15_suppl.4513
• Publication Date: 2018-09-05T10:31:06Z
• Authors: Markus Joerger; Philippe Alexandr...; Nicolas Penel; Richard Cathomas; Heike Richly; Martin Schostak; Andreas Janitzky; Martin Wermke; Lucia Nogova; David Wai-Meng Tai; Cyrus Sayehli; Carsten Grüllich; Enrique Grande; Alejandro Navarro; Se Hoon Park; Hendrik Nogai; Sebastian Bender; Peter Ellinghaus; Martin H. Schuler
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Medizin; 3. Good health

4513Background: Activation of FGFR signaling is involved in a variety of malignancies including advanced urothelial cancer (UC). Rogaratinib is an oral pan-FGFR kinase inhibitor. We report here the...